Disproportionate utilization of healthcare resources among veterans with COPD: A retrospective analysis of factors associated with COPD healthcare cost

Cost Effectiveness and Resource Allocation

Volumn 11, Issue 1, 2013, Pages

  Darnell, Kyle ^a,b   Dwivedi, Alok Kumar ^b   Weng, Zhouyang ^b   Panos, Ralph J ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

COPD; Cost; Healthcare utilization; Veterans healthcare administration

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYGEN; THEOPHYLLINE;

ARTICLE; BODY MASS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; DECISION SUPPORT SYSTEM; DIABETES MELLITUS; DRUG COST; EMERGENCY WARD; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LUNG EMPHYSEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NURSING HOME; OXYGEN THERAPY; PATIENT SELECTION; PRESCRIPTION; RETROSPECTIVE STUDY; RISK FACTOR; VETERAN; VHA DECISION SUPPORT SYSTEM;

EID: 84878815180     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-11-13     Document Type: Article

References (42)

1. Murphy D, Chaudhry Z, Almoosa K, Panos R. High prevalence of chronic obstructive pulmonary disease among veterans in the urban midwest. Mil Med 2011, 176(5):552-560.
2. McDonald M, Hertz R. Prizer Facts: Utilization of Verterans Affairs Medical Care Services by United States Veterans. The University of HawaI'I System. May 2003 Available at: http://www.hawaii.edu/hivandaids/Utilization%20of%20Veterans%20Affairs%20Medical%20Care%20Services%20by%20US%20Veterans.pdf. Accessed June 2012.
3. Committe On Veterans' Affairs House Commitee on Veterans Affairs. November 6, 2010 http://archives.veterans.house.gov/Media/File/111/9-29-10health/VARepQFR.htm. Accessed June 2012, Committe On Veterans' Affairs.
4. Seemungal T, Donaldson G, Bhowmik A, Jeffries D, Wedzicha J. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161(5):1608-1613. 10.1164/ajrccm.161.5.9908022, 10806163.
5. Seemungal T, Donaldson G, Paul E, Bestall J, Jeffries D, Wedzicha J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157(5 Pt 1):1418-1422.
6. Connors AJ, Dawson N, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996, 154(4 Pt 1):959-967.
7. Cao Z, Ong K, Eng P, Tan W, Ng T. Frequent hospital readmissions for acute exacerbation of COPD and their associated factors. Respirology 2006, 11(2):188-195. 10.1111/j.1440-1843.2006.00819.x, 16548905.
8. Hilleman D, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000, 118(5):1278-1285. 10.1378/chest.118.5.1278, 11083675.
9. Wilson L, Devine E, So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 2000, 94(3):204-213. 10.1053/rmed.1999.0720, 10783930.
10. Niewoehner D, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest 2007, 131(1):20-28. 10.1378/chest.06-1316, 17218552.
11. Osman I, Godden D, Friend J, Legge J, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997, 52(1):67-71. 10.1136/thx.52.1.67, 1758400, 9039248.
12. Garcia-Aymerich J, Barreiro E, Farrero E, RM M, Morera J, Anto J. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur Respir J 2000, 16(6):1037-1042. 10.1034/j.1399-3003.2000.16f03.x, 11292102.
13. Lau A, Yam L, Poon E. Hospital re-admission in patients with acute exacerbation of chronic obstructive pulmonary disease. Respir Med 2001, 95(11):876-884. 10.1053/rmed.2001.1180, 11716201.
14. Gudmundsson G, Gislason T, Janson C, et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J 2005, 26(3):414-419. 10.1183/09031936.05.00078504, 16135721.
15. Garcia-Americh J, Farrero E, Felez M, et al. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003, 58(2):100-105. 10.1136/thorax.58.2.100, 1746561, 12554887.
16. Garcia-Aymerich J, Monso E, Marrades R, et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. Am J Respir Crit Care Med Sep 2001, 164(6):1002-1007.
17. Erelel M, Cunhadaroglu C, Ece T, Arseven O. The frequency of deep venous thrombosis and pulmonary embolus in acute exacerbation of chronic obstructive pulmonary disease. Respir Med 2002, 96(7):515-518. 10.1053/rmed.2002.1313, 12194636.
18. Greene C, Bradley K, Bryson C, et al. The association between alcohol consumption and risk of COPD exacerbation in a veteran population. Chest 2008, 134(4):761-767. 10.1378/chest.07-3081, 18625671.
19. Blamoun A, Batty G, DeBari V, Rashid A, Sheikh M, Khan M. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 2008, 62(9):1373-1378. 10.1111/j.1742-1241.2008.01731.x, 18422598.
20. Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003, 58(1):37-42. 10.1136/thorax.58.1.37, 1746460, 12511718.
21. Quint J, Baghai-Ravary R, Donaldson G, Wedzicha J. Relationship between depression and exacerbations in COPD. Eur Respir J 2008, 32(1):53-60. 10.1183/09031936.00120107, 18321938.
22. McGhan R, Radcliff T, Rish R, Sutherland E, Welsh C, Make B. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007, 132(6):1748-1755. 10.1378/chest.06-3018, 17890477.
23. Kessier R, Faller M, Fourgaut G, Meenecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 159(1):158-164. 10.1164/ajrccm.159.1.9803117, 9872834.
24. Marin J, Carrizo S, Casanova C, et al. Prediction of risk of COPD exacerbations by the BODE index. Respir Med 2009, 103(3):373-378. 10.1016/j.rmed.2008.10.004, 19013781.
25. Groenewegen K, Postma D, Hop W, et al. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008, 133(2):350-357. 10.1378/chest.07-1342, 18198263.
26. Hurst J, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138. 10.1056/NEJMoa0909883, 20843247.
27. Sharafkhaneh A, Petersen N, Yu HJ, Dalal A, Johnson M, Hanania N. Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population. Int J COPD 2010, 5:125-132.
28. Yu W, Ravelo A, Wagner T, et al. Prevalence and costs of chronic conditions in the VA health care system. Med Care Res Rev 2003, 60(3 Suppl):146S-167S.
29. Wouters E. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003, 97(Suppl C):S3-S14.
30. Menzin J, Boulanger L, Marton J, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med 2008, 102(9):1248-1256. 10.1016/j.rmed.2008.04.009, 18620852.
31. Simon-Tuval T, Scharf S, Maimon N, Bernhard-Scharf B, Reuveni H, Tarasiuk A. Determinants of elevated healthcare utilization in patients with COPD. Respir Res 2011, 12(7).
32. Shaya F, Lin P, Aljawadi M, Scharf S. Elevated economic burden in obstructive lung disease patients with concomitant sleep apnea syndrome. Sleep Breath 2009, 13(4):317-323. 10.1007/s11325-009-0266-2, 19484281.
33. Akazawa M, Jalpern R, Riedel A, Stanford R, Dalal A, Blanchette C. Economic burden prior to COPD diagnosis: a matched case-control study in the United States. Respir Med 2008, 102(12):1744-1752. 10.1016/j.rmed.2008.07.009, 18760581.
34. Mapel D, Robinson S, Dastani H, Shah H, Phillips A, Lydick E. The direct medical costs of undiagnosed chronic obstructive pulmonary disease. Value Health 2008, 11(4):628-636. 10.1111/j.1524-4733.2007.00305.x, 18194402.
35. Stanton M, Rutherford M. The high concentration of U.S. health care expenditures 2005, Rockville (MD): Agency for Healthcare Research and Quality, Pub. No. 06-0060.
36. Teo W, Tan WS, Chong W, et al. Economic burden of chronic obstructive pulmonary disease. Respirology 2012, 17(1):120-126. 10.1111/j.1440-1843.2011.02073.x, 21954985.
37. Masa J, Sobradillo V, Villasante C, et al. Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study. Arch Bronconeumol 2004, 40(2):72-79.
38. Jacobson L, Hertzman P, Lofdahl C, Skogh B, Lindgren B. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir Med 2000, 94(3):247-255. 10.1053/rmed.1999.0733, 10783936.
39. Elizhauser A, Au D, Podulka J. Readmissions for Chronic Obstructive Pulmonary Disease, 2008 2011, Rockville, MD: Agency for Healthcare REsearch and Quality, HCUP Statistical Brief #121.
40. Miravitlles M, Murio C, Guerrero T, Gisber R, EPOC DSGDsAyFel Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002, 121(5):1449-1455. 10.1378/chest.121.5.1449, 12006427, EPOC DSGDsAyFel.
41. Dal Negro R, Berto P, Tognella S, Quareni L. Global outcomes in lung disease study group. Cost-of-illness of lung disease in the TriVeneto region, Italy: the GOLD study. Monaldi Arch Chest Dis 2002, 57(1):3-9.
42. Miravilles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003, 123(3):784-791. 10.1378/chest.123.3.784, 12628879.